46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study.

Hubert H Fernandez,David Stamler,Mat D Davis,Stewart A Factor,Robert A Hauser,Joohi Jimenez-Shahed,William G Ondo,L Fredrik Jarskog,Scott W Woods,Mark S LeDoux,David R Shprecher,Karen E Anderson

CNS spectrums（2019）

Cited 1|Views145

No score

Abstract

These results confirm the safety outcomes seen in the ARM-TD and AIM-TD parent studies, demonstrating that deutetrabenazine is well tolerated for long-term use in TD patients.Presented at: American Academy of Neurology Annual Meeting; April 21-27, 2018, Los Angeles, California,USAFunding Acknowledgements: Funding: This study was supported by Teva Pharmaceuticals, Petach Tikva, Israel.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined